Search

Your search keyword '"Moog, Gero"' showing total 118 results

Search Constraints

Start Over You searched for: Author "Moog, Gero" Remove constraint Author: "Moog, Gero"
118 results on '"Moog, Gero"'

Search Results

3. Anatomie und Physiologie

5. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

7. Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal

9. Gemeinsames Positionspapier der DGVS, der DEGEA, der DGE-BV, des BVGD, der ALGK und des bng zum aktuellen Stand und den prinzipiellen Möglichkeiten der Delegation ärztlicher Tätigkeiten im Bereich Gastroenterologie (für Klinik und Praxis)

10. Colon capsule endoscopy: indications, findings, and complications – data from a prospective german colon capsule registry trial (DEKOR)

11. Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten (DGVS)

12. Neufassung der Standard-Terminologie in der gastroenterologischen Endoskopie – Ergebnis eines Konsensusprojekts der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten

24. Benefit of treatment individualization in patients with chronic hepatitis C receiving peginterferon alfa-2a and ribavirin in a large noninterventional cohort study

26. Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study

34. Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3

39. Sa1050 Efficacy of Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1: The PAN Study

40. Sa1051 Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment NaïVE Patients Infected With Chronic Hepatitis C, Genotype 1: An Interim Analysis At Week 12 After Start of Treatment

41. 723 Substantial Renal Impairment Is Not Infrequent in HCV Patients Under Triple Therapy With Telaprevir or Boceprevir

42. Sa1041 Triple Therapy Under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1. the PAN Study

43. Sa1052 Triple Therapy Under Real Life Conditions: Telaprevir (TVR) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in NaïVE Patients Infected With Chronic Hepatitis C, Genotype 1. The PAN Study

45. Sa1059 Viral Response at Week 2 as a Predicitive Factor for Rvr in Chronic Hepatitis C Genotype 1 Infection Treated With Peginterferon Alfa-2A (PEG) and Ribavirin (RBV)

46. 940 Predicitive Factors for Nonresponse in Genotype 2/3 Infected Chronic Hepatitis C (CHC) Patients Treated With Peginterferon Alfa-2A (PEG) and Ribavirin (RBV) in Real Life Setting

47. Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin

49. M1794 Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) (PEG) and Ribavirin (RBV) in Genotype 5 and 6 Patients with Chronic Hepatitis C Under Real Life Conditions

50. M1791 Role of Rvr and Viral Load On SVR in Treatment of GT3 Hepatitis C Patients with Peginterferon Alfa-2a (PEG) and Ribavirin (RBV) in Real Life

Catalog

Books, media, physical & digital resources